Fiche centre
Rajavithi Hospital
Bangkok — Thailand
Essais liés6clinical trials
VilleBangkoklocalisation
PaysThailandlocalisation
SourcelocaleCSV/MySQL
Informations
centreSynchronisé depuis ClinicalTrials.gov — NCT06757634
Essais cliniques associés
6| Molécule | Indication / population | Phase | NCT | Titre | Statut |
|---|---|---|---|---|---|
| Arm A: Gedatolisib + Palbociclib + Fulvestrant | Cancer | Phase 3 | NCT06757634 | Phase 3 Study of Gedatolisib as First-Line Treatment for Patients With HR-Positive, HER2-Negative Advanced Breast Cancer (VIKTORIA-2) | RECRUITING |
| Giredestrant | Cancer | Phase 3 | NCT06065748 | A Study to Evaluate Efficacy and Safety of Giredestrant Compared With Fulvestrant (Plus a CDK4/6 Inhibitor), in Participants With ER-Positive, HER2-Negative Advanced Breast Cancer Resistant to Adjuvant Endocrine Therapy (pionERA Breast Cancer) | ACTIVE_NOT_RECRUITING |
| RNASc — Rajavtihi Neuronal Adult Stem Cells Project | SEP | Phase 2 | NCT00927108 | RNASc — Rajavtihi Neuronal Adult Stem Cells Project | WITHDRAWN |
| Cenerimod | Lupus | Phase 3 | NCT06475742 | OPUS OLE — Long-term Safety and Tolerability of Cenerimod in Adults With Systemic Lupus Erythematosus | ENROLLING_BY_INVITATION |
| Cenerimod | Lupus | Phase 3 | NCT05648500 | OPUS-1 — A Research Study to Evaluate the Effects of a New Oral Medicine Called Cenerimod in Adults With Systemic Lupus Erythematosus | ACTIVE_NOT_RECRUITING |
| Cenerimod 0.5 mg | Lupus | Phase 2 | NCT03742037 | Efficacy and Safety of Four Doses of Cenerimod Compared to Placebo in Adult Subjects With Active Systemic Lupus Erythematosus | COMPLETED |